Figure 8.Immune checkpoint genes expression, IPSs and immunotherapy benefits of patients in the two risk groups. (A) The differences in immune checkpoint gene expression between the high-risk and low-risk groups. (B–E) CR/PR patients had significantly lower risk scores than SD/PD patients in the iMvigor210 (F), PRJEB25780 (G), PRJNB23709 (H), and GSE35640 (I) cohorts.
